Long-term improvement of hematopoiesis following cyclosporine treatment in a patient with myelodysplastic syndrome.
Current treatment of patients with myelodysplastic syndrome (MDS) is unsatisfactory. Very recently, immunosuppressive treatment strategies have been gaining interest. We report a patient with transfusion-dependent MDS who achieved significant hematopoietic improvement following cyclosporine (CsA) therapy and who is now transfusion independent for more than 5 years. This single observation supports the view that CsA, among other immunosuppressive agents, could play an important role in future treatment concepts in MDS and may lead to clinically relevant and sustained improvement of hematopoiesis in a subset of patients.
Berer
A
A
First Department of Medicine, University of Vienna, Austria.
Ohler
L
L
Simonitsch
I
I
Thalhammer
R
R
Lechner
K
K
Geissler
K
K
D000328:Adult; D000753:Anemia, Refractory / Q000188:drug therapy / Q000276:immunology; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D017707:Erythrocyte Transfusion; D005500:Follow-Up Studies; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000276:immunology; D017713:Platelet Transfusion; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D016572:Cyclosporine